Antitumoral Activity of (20 R)- and (20 S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice

Planta Medica

Volumn 82, Issue 8, 2016, Pages 705-711

  Lv, Qun ^a   Rong, Na ^a   Liu, Li Jia ^a   Xu, Xiao Lin ^a   Liu, Jian Ting ^a   Jin, Feng Xie ^b   Wang, Chun Mei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b DALIAN POLYTECHNIC UNIVERSITY   (China)

Author keywords

(20 R) ginsenoside Rh2; (20 S) ginsenoside Rh2; antitumor; apoptosis; ginsenoside; hepatocellular carcinoma; in vivo; mice

Indexed keywords

EOSIN; GINSENOSIDE RH 2; HEMATOXYLIN; MESSENGER RNA; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; GINSENOSIDE; HERBACEOUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG SCREENING; ISOMERISM; LIVER NEOPLASMS, EXPERIMENTAL; PANAX;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; FEMALE; GINSENOSIDES; ISOMERISM; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PANAX;

EID: 84967327805     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0042-101764     Document Type: Article

References (29)

1. Tan B., Huang J. F., Wei Q., Zhang H., Ni R. Z. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol: 2005; 11 5938 5943
2. Zhu Z. Z., Cong W. M., Liu S. F., Dong H., Zhu G. S., Wu M. C. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol: 2005; 11 289 292
3. Yue P. Y., Mak N. K., Cheng Y. K., Leung K. W., Ng T. B., Fan D. T., Yeung H. W., Wong R. N. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med: 2007; 2 6
4. Hwang J. T., Kim S. H., Lee M. S., Kim S. H., Yang H. J., Kim M. J., Kim H. S., Ha J., Kim M. S., Kwon D. Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3 T3-L1 adipocyte. Biochem Biophys Res Commun: 2007; 364 1002 1008
5. Wang H., Yu P., Gou H., Zhang J., Zhu M., Wang Z., Tian J., Jiang Y., Fu F. Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evid Based Complement Alternat Med: 2012; 2012 506214
6. Lian L. H., Jin Q., Song S. Z., Wu Y. L., Bai T., Jiang S., Li Q., Yang N., Nan J. X. Ginsenoside Rh2 downregulates LPS-induced NF- κ B activation through inhibition of TAK1 phosphorylation in RAW 264.7 murine macrophage. Evid Based Complement Alternat Med: 2013; 2013 646728
7. He L., Lee J., Jang J. H., Lee S. H., Nan M. H., Oh B. C., Lee S. G., Kim H. H., Soung N. K., Ahn J. S., Kim B. Y. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF- κ B, NFATc1 and c-Fos. Bone: 2012; 50 1207 1213
8. Wang Z., Zheng Q., Liu K., Li G., Zheng R. Ginsenoside Rh(2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Basic Clin Pharmacol Toxicol: 2006; 98 411 415
9. Dong H., Bai L. P., Wong V. K., Zhou H., Wang J. R., Liu Y., Jiang Z. H., Liu L. The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives. Molecules: 2011; 16 10619 10630
10. Yue P. YK, Huang Y., Wong R. NS. Ginsenoside Rg3 and Rh2: the anti-cancer and anti- angiogenic saponins from Ginseng. In: Atta-ur-Rahman, Iqbal Choudhary M. editors Anti-angiogenesis drug discovery and development, Vol. 1. Sharjah, U.A.E. Bentham e-Book: 2011; 34 57
11. Guo X. X., Guo Q., Li Y., Lee S. K., Wei X. N., Jin Y. H. Ginsenoside Rh2 induces human hepatoma cell apoptosis via bax/bak triggered cytochrome C release and caspase-9/caspase-8 activation. Int J Mol Sci: 2012; 13 15523 15535
12. Liu Y., Zhang X., Chen S., Zhao Y. Induce apoptosis effect of ginsenoside Rh2 on HepG2 cells. Zhongguo Shiyan Zhenduanxue: 2011; 15 2011 2013
13. He X., He J., Zhang Y. Effects of ginsenoside Rh2 on the proliferation and apoptosis of human hepatocarcinoma cells Bel-7402. China J Mod Med: 2012; 22 24 27.
14. Zeng X. L., Tu Z. G. Induction of differentiation by ginsenoside Rh2 in hepatocarcinoma cell SMMC-7721. Chin J Cancer: 2004; 23 879 884
15. Cao M., Zhang J., Zhao Y., Song X., Ma B. Advances in Ginsenoside Rh2 and Its Derivatives. World Sci Tech: 2012; 14 2205 2211
16. Melchert M., List A. The thalidomide saga. Int J Biochem Cell Biol: 2007; 39 1489 1499
17. FDA's policy statement on the development of new stereoisomeric drugs. Chirality: 1992; 4 338 340
18. Liu J., Shiono J., Shimizu K., Yu H., Zhang C., Jin F., Kondo R. 20 (R)-ginsenoside Rh2, not 20 (S), is a selective osteoclastgenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett: 2009; 19 3320 3323
19. Oh S. J., Lee S., Choi W. Y., Lim C. J. Skin anti-photoaging properties of ginsenoside Rh2 epimers in UV-B-irradiated human keratinocyte cells. J Biosci: 2014; 39 673 682
20. Liu J., Shimizu K., Yu H., Zhang C., Jin F., Kondo R. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia: 2010; 81 902 905
21. Tao L., Gao F., Fu Z., Han R. Inhibition effect of 20(R)-ginsenoside Rh2 skin tumor-bearing mice induced by DMBA/croton oil. Lishizhen Med Mater Med Res: 2006; 17 1950 1954
22. Tao L., Liu H., Han R. Inhibitory effect of 20(R)-ginsenoside Rh2 on B16 melanom a metastasis. Liaoning J Tradit Chin Med: 2006; 33 1505 1506
23. Gu Y., Wang G. J., Wu X. L., Zheng Y. T., Zhang J. W., Ai H., Sun J. G., Jia Y. W. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters. Xenobiotica: 2010; 40 602 612
24. Tawab M. A., Bahr U., Karas M., Wurglics M., Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos: 2003; 31 1065 1071
25. Zhang J., Zhou F., Niu F., Lu M., Wu X., Sun J., Wang G. Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics. PLoS One: 2012; 7 e35768
26. Bae S. H., Park J. B., Zheng Y. F., Jiang M. J., Kim S. O., Kim J. Y., Yoo Y. H., Yoon K. D., Oh E., Bae S. K. Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats. Xenobiotica: 2014; 44 1099 1107
27. Wu R., Ru Q., Chen L., Ma B., Li C. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice. J Food Sci: 2014; 79 H1430 H1435
28. Qian T., Cai Z., Wong R. N., Mak N. K., Jiang Z. H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci: 2005; 816 223 232
29. Fischer A. H., Jacobson K. A., Rose J., Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc: 2008; 2008 pdb.prot4986